Inovio Pharmaceuticals (INO) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Inovio Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$832.01M

Main Segment (Y)

License

Main Geography (Y)

License

Inovio Pharmaceuticals Revenue by Period

Inovio Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$832.01M	8007.47%
2022-12-31	$10.26M	478.23%
2021-12-31	$1.77M	-76.05%
2020-12-31	$7.41M	80.24%
2019-12-31	$4.11M	-86.51%
2018-12-31	$30.48M	-27.80%
2017-12-31	$42.22M	19.37%
2016-12-31	$35.37M	-12.83%
2015-12-31	$40.57M	288.00%
2014-12-31	$10.46M	-22.35%
2013-12-31	$13.47M	226.98%
2012-12-31	$4.12M	-57.95%
2011-12-31	$9.80M	59.41%
2010-12-31	$6.14M	-32.62%
2009-12-31	$9.12M	334.78%
2008-12-31	$2.10M	-56.37%
2007-12-31	$4.81M	38.62%
2006-12-31	$3.47M	-36.56%
2005-12-31	$5.47M	368.45%
2004-12-31	$1.17M	1349.29%
2003-12-31	$80.53K	-57.51%
2002-12-31	$189.52K	-95.74%
2001-12-31	$4.45M	-12.30%
2000-03-31	$5.08M	-38.83%
1999-03-31	$8.30M	-

Inovio Pharmaceuticals generated $832.01M in revenue during NA 2023, up 8007.47% compared to the previous quarter, and up 2729.52% compared to the same period a year ago.

Inovio Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	-	-100.00%
2024-06-30	$100.76K	100.00%
2024-03-31	-	-100.00%
2023-12-31	$102.65K	-73.57%
2023-09-30	$388.45K	71.90%
2023-06-30	$225.97K	96.59%
2023-03-31	$114.94K	-7.80%
2022-12-31	$124.67K	-98.64%
2022-09-30	$9.15M	1067.03%
2022-06-30	$784.39K	294.02%
2022-03-31	$199.07K	-76.28%
2021-12-31	$839.12K	187.67%
2021-09-30	$291.70K	6.92%
2021-06-30	$272.82K	-26.49%
2021-03-31	$371.12K	-93.35%
2020-12-31	$5.58M	2262.87%
2020-09-30	$236.18K	-11.61%
2020-06-30	$267.19K	-79.87%
2020-03-31	$1.33M	374.89%
2019-12-31	$279.49K	-67.76%
2019-09-30	$866.86K	538.94%
2019-06-30	$135.67K	-95.21%
2019-03-31	$2.83M	13.08%
2018-12-31	$2.50M	25.08%
2018-09-30	$2.00M	-91.82%
2018-06-30	$24.45M	1498.33%
2018-03-31	$1.53M	-82.59%
2017-12-31	$8.79M	232.28%
2017-09-30	$2.64M	-87.04%
2017-06-30	$20.41M	96.72%
2017-03-31	$10.38M	21.87%
2016-12-31	$8.51M	-32.11%
2016-09-30	$12.54M	102.14%
2016-06-30	$6.20M	-23.51%
2016-03-31	$8.11M	36.64%
2015-12-31	$5.94M	-75.46%
2015-09-30	$24.18M	357.44%
2015-06-30	$5.29M	2.32%
2015-03-31	$5.17M	110.27%
2014-12-31	$2.46M	33.51%
2014-09-30	$1.84M	-51.59%
2014-06-30	$3.80M	61.25%
2014-03-31	$2.36M	35.52%
2013-12-31	$1.74M	-81.66%
2013-09-30	$9.49M	1107.58%
2013-06-30	$785.61K	-46.01%
2013-03-31	$1.46M	28.24%
2012-12-31	$1.13M	32.77%
2012-09-30	$854.70K	95.99%
2012-06-30	$436.08K	-74.24%
2012-03-31	$1.69M	3.70%
2011-12-31	$1.63M	-38.10%
2011-09-30	$2.64M	9.00%
2011-06-30	$2.42M	-22.08%
2011-03-31	$3.11M	31.58%
2010-12-31	$2.36M	84.87%
2010-09-30	$1.28M	12.48%
2010-06-30	$1.13M	-17.37%
2010-03-31	$1.37M	-47.43%
2009-12-31	$2.61M	-28.35%
2009-09-30	$3.65M	46.35%
2009-06-30	$2.49M	574.40%
2009-03-31	$369.45K	13.03%
2008-12-31	$326.85K	-28.12%
2008-09-30	$454.74K	-31.42%
2008-06-30	$663.03K	1.53%
2008-03-31	$653.01K	-80.34%
2007-12-31	$3.32M	-

Inovio Pharmaceuticals generated - in revenue during Q3 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Inovio Pharmaceuticals Revenue Breakdown

Inovio Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 21	Dec 20	Dec 19
Other Revenue Affiliated Entity	-	-	-
Other Revenue	$627.19K	$786.90K	-
License with Affiliated Entities	$245.31K	$1.45M	$235.65K
License	$902.26K	$5.17M	$3.64M
Grant with Affiliated Revenue	-	-	$1.80K
Grant	-	-	$237.54K

Inovio Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 21: License (50.84%), Other Revenue (35.34%), and License with Affiliated Entities (13.82%).

Quarterly Revenue by Product

Product/Service	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
License With Affiliated Entities	$7.00K	$6.21K	-	-	-	-	-	-	-	-	-	-	-	-	-
License	-	$36.84K	$65.89K	$698.27K	$81.45K	$82.92K	$39.62K	$5.00M	$21.49K	$74.10K	$71.50K	$184.52K	$617.43K	$64.28K	$2.77M
Product and Service, Other	-	$741.34K	$124.34K	$115.11K	$115.11K	$281.56K	$111.00K	$97.94K	$83.65K	$39.30K	$196.42K	-	$3.61K	-	-
License with Affiliated Entities	-	-	$8.84K	$25.44K	$95.14K	$74.79K	$49.95K	$82.77K	$103.68K	$95.15K	$1.17M	$55.66K	$53.01K	$71.39K	$55.58K
Other Revenue Affiliated Entity	-	-	-	-	-	-	-	$494.31K	-	-	-	-	-	-	-

Inovio Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: License With Affiliated Entities (100.00%).

Inovio Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 21	Dec 20	Dec 19
License with Affiliated Entities	$245.31K	$1.45M	$235.65K
Other Revenue	$627.19K	$786.90K	-
License	$902.26K	$5.17M	$3.64M
Other Revenue Affiliated Entity	-	-	-
Grant with Affiliated Revenue	-	-	$1.80K
Grant	-	-	$237.54K

Inovio Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 21: License (50.84%), Other Revenue (35.34%), and License with Affiliated Entities (13.82%).

Quarterly Revenue by Country

Country	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
License With Affiliated Entities	$7.00K	$6.21K	-	-	-	-	-	-	-	-	-	-	-	-	-
License	-	$36.84K	$65.89K	$698.27K	$81.45K	$82.92K	$39.62K	$5.00M	$21.49K	$74.10K	$71.50K	$184.52K	$617.43K	$64.28K	$2.77M
Product and Service, Other	-	$741.34K	$124.34K	$115.11K	$115.11K	$281.56K	$111.00K	$97.94K	$83.65K	$39.30K	$196.42K	-	$3.61K	-	-
License with Affiliated Entities	-	-	$8.84K	$25.44K	$95.14K	$74.79K	$49.95K	$82.77K	$103.68K	$95.15K	$1.17M	$55.66K	$53.01K	$71.39K	$55.58K
Other Revenue Affiliated Entity	-	-	-	-	-	-	-	$494.31K	-	-	-	-	-	-	-

Inovio Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 22: License With Affiliated Entities (100.00%).

Inovio Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
NVAX	Novavax	$983.71M	$415.48M
INO	Inovio Pharmaceuticals	$832.01M	-
VXRT	Vaxart	$7.38M	$4.93M
CWBR	CohBar	-	-
AVRO	AVROBIO	-	-
ELEV	Elevation Oncology	-	-
OCEA	Ocean Biomedical	-	-
HEPA	Hepion Pharmaceuticals	-	-
ENVB	Enveric Biosciences	-	-

INO Revenue FAQ

What is Inovio Pharmaceuticals’s yearly revenue?

Inovio Pharmaceuticals's yearly revenue for 2023 was $832.01M, representing an increase of 8007.47% compared to 2022. The company's yearly revenue for 2022 was $10.26M, representing an increase of 478.23% compared to 2021. INO's yearly revenue for 2021 was $1.77M, representing a decrease of -76.05% compared to 2020.

What is Inovio Pharmaceuticals’s quarterly revenue?

Inovio Pharmaceuticals's quarterly revenue for Q3 2024 was $0, a -100.00% decrease from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $100.76K, a 100.00% increase from the previous quarter (Q1 2024), and a -55.41% decrease year-over-year (Q2 2023). INO's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023).

What is Inovio Pharmaceuticals’s revenue growth rate?

Inovio Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 46780.19%, and for the last 5 years (2019-2023) was 20134.05%.

What are Inovio Pharmaceuticals’s revenue streams?

Inovio Pharmaceuticals's revenue streams in c 21 are Other Revenue, License with Affiliated Entities, and License. Other Revenue generated $627.19K in revenue, accounting 35.34% of the company's total revenue, down -20.30% year-over-year. License with Affiliated Entities generated $245.31K in revenue, accounting 13.82% of the company's total revenue, down -83.13% year-over-year. License generated $902.26K in revenue, accounting 50.84% of the company's total revenue, down -82.55% year-over-year.

What is Inovio Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Inovio Pharmaceuticals was License. This segment made a revenue of $902.26K, representing 50.84% of the company's total revenue.